Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Aquatic Capital Management LLC

Aquatic Capital Management LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 128.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,081 shares of the biopharmaceutical company's stock after buying an additional 15,241 shares during the quarter. Aquatic Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $19,291,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of REGN. Virtu Financial LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $6,364,000. Morse Asset Management Inc grew its stake in Regeneron Pharmaceuticals by 0.9% during the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company's stock valued at $5,053,000 after purchasing an additional 43 shares in the last quarter. Anchor Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 212.0% during the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company's stock valued at $902,000 after purchasing an additional 583 shares in the last quarter. Sculati Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company's stock valued at $1,970,000 after purchasing an additional 38 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co grew its stake in Regeneron Pharmaceuticals by 19.0% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company's stock valued at $5,575,000 after purchasing an additional 848 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Bank of America lowered their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $945.32.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $41.95 during mid-day trading on Tuesday, hitting $568.91. 2,623,792 shares of the company's stock traded hands, compared to its average volume of 735,619. The firm has a 50 day moving average price of $635.89 and a 200 day moving average price of $719.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $62.20 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the firm earned $9.55 EPS. The firm's revenue was down 3.7% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.